[go: up one dir, main page]

AR115256A1 - Sistemas de vectores virales recombinantes que expresan genes de paramixovirus felino exógenos y vacunas elaboradas a partir de estos - Google Patents

Sistemas de vectores virales recombinantes que expresan genes de paramixovirus felino exógenos y vacunas elaboradas a partir de estos

Info

Publication number
AR115256A1
AR115256A1 ARP190100431A ARP190100431A AR115256A1 AR 115256 A1 AR115256 A1 AR 115256A1 AR P190100431 A ARP190100431 A AR P190100431A AR P190100431 A ARP190100431 A AR P190100431A AR 115256 A1 AR115256 A1 AR 115256A1
Authority
AR
Argentina
Prior art keywords
feline
nucleic acid
acid sequence
seq
viral vector
Prior art date
Application number
ARP190100431A
Other languages
English (en)
Inventor
Teshome Mebatsion
Smit Abraham Johannes De
Veljko Nikolin
Herv Poulet
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Boehringer Ingelheim Animal Health Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh, Boehringer Ingelheim Animal Health Usa Inc filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of AR115256A1 publication Critical patent/AR115256A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Genes de paramixovirus felino exógenos que se expresan de sistemas de vectores virales recombinantes. Reivindicación 1: Un vector viral recombinante y/o no natural, caracterizado porque comprende al menos una secuencia codificante de antígeno exógena de o relacionada con al menos un patógeno que infecta felinos, en donde el al menos un patógeno que infecta felinos es paramixovirus felino. Reivindicación 3: El vector viral de acuerdo con cualquiera de las reivindicaciones 1 a 2, caracterizado porque el al menos un patógeno que infecta felinos que es paramixovirus felino se selecciona del grupo que consiste en: (a) un paramixovirus felino tipo 2 (FPaV-2); (b) un paramixovirus felino tipo 2 (FPaV-2), cuyo genoma comprende un ácido ribonucleico complementario con la secuencia de ácido nucleico seleccionada del grupo que consiste en: (i) una secuencia de ácido nucleico de acuerdo con SEQ ID Nº 1, (ii) una secuencia de ácido nucleico que es al menos 70% idéntica a SEQ ID Nº 1; (c) paramixovirus felino tipo 2 (FPaV-2) según está depositado en Collection Nationale de Culture de Microorganismes (CNCM) con el número de acceso CNCM I-5123; (d) un paramixovirus felino tipo 2 (FPaV-2), cuyo genoma comprende un ácido ribonucleico complementario con la secuencia de ácido nucleico seleccionada del grupo que consiste en: (i) una secuencia de ácido nucleico de acuerdo con SEQ ID Nº 2; (ii) una secuencia de ácido nucleico que es al menos 70% idéntica a SEQ ID Nº 2; (e) un morbillivirus felino (FeMov); (f) un morbillivirus felino (FeMoV), cuyo genoma comprende un ácido ribonucleico complementario con la secuencia de ácido nucleico seleccionada del grupo que consiste en: (i) una secuencia de ácido nucleico de acuerdo con SEQ ID Nº 3; (ii) una secuencia de ácido nucleico que es al menos 70% idéntica a SEQ ID Nº 3.
ARP190100431A 2018-02-23 2019-02-20 Sistemas de vectores virales recombinantes que expresan genes de paramixovirus felino exógenos y vacunas elaboradas a partir de estos AR115256A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18158450 2018-02-23

Publications (1)

Publication Number Publication Date
AR115256A1 true AR115256A1 (es) 2020-12-16

Family

ID=61526550

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190100431A AR115256A1 (es) 2018-02-23 2019-02-20 Sistemas de vectores virales recombinantes que expresan genes de paramixovirus felino exógenos y vacunas elaboradas a partir de estos

Country Status (15)

Country Link
US (1) US11033616B2 (es)
EP (1) EP3668988B1 (es)
JP (1) JP2021514196A (es)
KR (1) KR20200124713A (es)
CN (1) CN111712575B (es)
AR (1) AR115256A1 (es)
AU (1) AU2019223768A1 (es)
BR (1) BR112020017239A2 (es)
CA (1) CA3088646A1 (es)
EA (1) EA202091958A1 (es)
ES (1) ES3042364T3 (es)
HU (1) HUE072901T2 (es)
MX (1) MX2020008779A (es)
TW (1) TW201942355A (es)
WO (1) WO2019162294A1 (es)

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US382425A (en) 1888-05-08 Brandt
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4769331A (en) 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
JPS60500673A (ja) 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン 抗原活性を有するアミノ酸配列
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
IL84154A0 (en) 1986-10-16 1988-03-31 Microgenesys Inc Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
WO1990001543A1 (fr) 1988-07-29 1990-02-22 Intracel Corporation Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo
CA2003300A1 (en) 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DK0737750T3 (da) 1989-03-21 2003-09-01 Vical Inc Ekspression af exogene polynucleotidsekvenser i vertebrater
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
US5552143A (en) 1989-03-24 1996-09-03 The Wistar Institute Of Anatomy & Biology Recombinant cytomegalovirus vaccine
GB9001766D0 (en) 1990-01-25 1990-03-28 Univ Court Of The University O Vaccines
EP0575491B1 (en) 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
IL108915A0 (en) 1993-03-18 1994-06-24 Merck & Co Inc Polynucleotide vaccine against influenza virus
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
EP1170368B1 (en) 1994-01-27 2010-07-28 University Of Massachusetts Medical Center Immunization by inoculation of dna transcription unit
WO1995030018A2 (en) 1994-04-29 1995-11-09 Immuno Aktiengesellschaft Recombinant poxviruses with foreign polynucleotides in essential regions
CA2215162A1 (en) 1995-03-23 1996-09-26 Cantab Pharmaceuticals Research Limited Vectors for gene delivery
EP0979101B1 (en) 1996-07-03 2010-10-27 Merial, Inc. Recombinant canine adenovirus 2 (cav2) containing exogenous dna
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
EP1670508B1 (en) 2003-02-28 2012-10-24 Trustees Of The University Of Pennsylvania Compositions, methods and kits relating to poxvirus subunit vaccines
DK1773387T3 (da) 2004-06-25 2013-07-15 Merial Ltd Avipox-rekombinanter der udtrykker mund- og klovesyge-virusgener
HRP20100314T1 (hr) 2005-04-25 2010-08-31 Merial Ltd. Cjepivo protiv nipah virusa
HRP20130888T1 (hr) 2008-07-23 2013-10-25 Boehringer Ingelheim Pharma Gmbh & Co.Kg. Novi regulacijski elementi
CN104471064B (zh) * 2012-01-20 2018-11-02 中华人民共和国香港特别行政区政府 副粘病毒及其用途
EP3466443B1 (en) 2012-02-14 2020-12-16 Boehringer Ingelheim Animal Health USA Inc. Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom
JP6589159B2 (ja) 2014-04-01 2019-10-16 共立製薬株式会社 新規ネコモルビリウイルス株、不活化ワクチン製剤、並びにネコモルビリウイルス感染症予防方法
TWI860276B (zh) * 2016-08-25 2024-11-01 德商百靈佳殷格翰維美迪加股份有限公司 新穎之副黏液病毒及其用途

Also Published As

Publication number Publication date
CN111712575B (zh) 2024-07-19
AU2019223768A1 (en) 2020-08-27
EP3668988A1 (en) 2020-06-24
HUE072901T2 (hu) 2025-12-28
JP2021514196A (ja) 2021-06-10
ES3042364T3 (en) 2025-11-20
KR20200124713A (ko) 2020-11-03
MX2020008779A (es) 2020-10-01
US20200206339A1 (en) 2020-07-02
EP3668988B1 (en) 2025-07-23
EA202091958A1 (ru) 2021-02-04
US11033616B2 (en) 2021-06-15
CA3088646A1 (en) 2019-08-29
WO2019162294A1 (en) 2019-08-29
TW201942355A (zh) 2019-11-01
CN111712575A (zh) 2020-09-25
BR112020017239A2 (pt) 2020-12-22

Similar Documents

Publication Publication Date Title
CL2021002739A1 (es) Proteína crispr de prevotella y francisella 1 (cpf1) aislada de acidaminococcus sp. bv3l6; proteína de fusión que la comprende; ácido nucleico; vector; métodos para alterar el genoma de una célula o una molécula de adn bicatenario in vitro que utilizan dichas proteínas (divisional de sol. 201903004)
AR014653A1 (es) Genes y promotores de la familia del maiz pr1, molecula de acido nucleico aislada, construccion de adn, vector, celula huesped, metodo para inducir laexpresion de una secuencia nucleotidica heterologa en una planta, metodo para expresar en forma constituyente una secuencia nucleotidica heterologa en
AR090417A1 (es) Plantas resistentes al glifosato y metodos asociados
RU2022103603A (ru) Направляемые нуклеиновыми кислотами нуклеазы
Jeong et al. Characterization of the DNA nucleotide sequences in the genome of red sea bream iridoviruses isolated in Korea
JP2013507935A5 (es)
RU2008125815A (ru) Теломеразная обратная транскриптаза птиц
NZ601950A (en) Method for producing pyripyropene
CL2022003484A1 (es) Monocotiledóneas heterocigotas con cenh3 y métodos de uso de estas para inducción de haploides y edición simultánea del genoma.
RU2017121232A (ru) Плазмиды и способ получения вирусных частиц
CN103805635B (zh) 一种基于J亚群禽白血病病毒env基因保守序列的siRNA重组干扰载体及其制备方法和应用
AR115256A1 (es) Sistemas de vectores virales recombinantes que expresan genes de paramixovirus felino exógenos y vacunas elaboradas a partir de estos
AR102803A1 (es) Vacunas de reovirus aviar
CN116656730B (zh) 一种表达狂犬病病毒g、m蛋白的重组金丝雀痘病毒及其构建方法
CN101575616A (zh) 禽流感和马立克氏病二联活疫苗rMDV-HA病毒株及构建方法
MX2021002374A (es) Metodos y composiciones para producir un virus.
AR110626A1 (es) Paramixovirus y sus usos
CN118325903A (zh) 一种用于靶向敲除鸡TRIM45基因的sgRNA、TRIM45敲除细胞系及其应用
KR101677231B1 (ko) 무혈청배지（serum free medium）를 이용한 메갈로사이티바이러스의 효율적 제조방법
AR113336A1 (es) Un método para incrementar el rendimiento de un cultivo que comprende transformar una planta con por lo menos una secuencia que codifica la proteína ferredoxina-tiorredoxina reductasa, constructo y planta
CN105132437B (zh) 表达鼠伤寒沙门菌OmpL蛋白的重组猪痘病毒载体疫苗
CN111004783A (zh) 一种表达猪圆环病毒2型cap蛋白的重组羊口疮病毒，其制备方法及应用
US10526393B2 (en) Method for promoting virus infection and increasing virus production, by using cell line having lost BST2 gene functions
CN103937833A (zh) 一种基于J亚群禽白血病病毒LTR基因保守序列的siRNA重组干扰载体及其制备方法和应用
CN117511968B (zh) 表达SARS-CoV-2的S、E和M蛋白的重组金丝雀痘病毒及其构建方法和应用

Legal Events

Date Code Title Description
FA Abandonment or withdrawal